Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Manne on the Need for Novel Therapies in HCC Without Preserved Liver Function

January 3rd 2022

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

Practice-Changing Data From 2021 Sets Tone for New Year

December 29th 2021

Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types.

Immunotherapy Approvals Overcome Years of Stagnation in GI Cancers

December 28th 2021

Syma Iqbal, MD, shares the main highlights from an IPC meeting, which centered on the evolving landscapes and importance of implementing best practices for patients with hepatobiliary cancers, locally advanced and advanced pancreatic cancer, advanced gastric/gastroesophageal junction cancer, and metastatic colorectal cancer.

Sequencing Strategies May Shift With Emerging Options in GI Malignancies

December 24th 2021

With the rapid uptake of novel therapies, including immunotherapy and targeted therapy, shifts in treatment strategies are anticipated in hepatobiliary cancers, locally advanced and advanced pancreatic cancer, gastric/gastroesophageal junction cancers, and metastatic colorectal cancer.

FDA Approval Sought for EirGenix Trastuzumab Biosimilar for HER2+ Breast and Gastric Cancers

December 21st 2021

A biologics license application has been submitted to the FDA seeking the approval of a proposed biosimilar for trastuzumab, a monoclonal antibody that is utilized in the treatment of patients with HER2-positive breast cancer and metastatic gastric cancers.

Hochster Underscores Headway Made in Gastric/GEJ Cancers

December 16th 2021

Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combinations, ongoing research with biomarkers of response, and optimal treatment sequencing for patients with HER2-positive disease.

Dr. Vaishampayan on the Utility of FGFR Inhibitors in Urothelial Cancer

December 8th 2021

Ulka Nitin Vaishampayan, MBBS, discusses the utility of FGFR inhibitors in metastatic urothelial cancer.

ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

December 6th 2021

Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.

Future Directions for HCC Management

December 1st 2021

Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.

Management of Advanced HCC Associated With NASH

December 1st 2021

Stephen L. Chan, MD, leads the discussion on the prevalence and management of advanced HCC in patients with NASH.

Treatment Options for Advanced HCC With Underlying NASH

December 1st 2021

A panel of experts in gastroenterology review the case of a 65-year-old man with advanced HCC associated with NASH and comment on treatment with TKIs and immunotherapy.

Investigators Still Working to Understand the Causes of Rare Gastric Cancer

December 1st 2021

Investigators have known about hereditary diffuse gastric cancer syndrome for decades, but only identified its molecular causes in the 1990s, said gastrointestinal oncologist Bryson Katona, MD, PhD.

Frontline Pembrolizumab Plus Chemotherapy Approved in Japan for Esophageal Carcinoma

November 30th 2021

The Japan Pharmaceuticals and Medical Devices Agency has approved the PD-1 inhibitor pembrolizumab for frontline use in combination with 5-fluorouracil plus cisplatin chemotherapy in patients with radically unresectable, advanced, or recurrent esophageal carcinoma.

Role of Genomic Testing in mCRC

November 30th 2021

Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.

Overview of Colorectal Cancer

November 30th 2021

Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.

Hochster Shares Best Practices on Molecular Markers and Sequencing in Gastric Cancer

November 29th 2021

Howard S. Hochster, MD, discusses molecular markers for patients with gastric cancer, using gene expression profiles as biomarkers, and choosing between anti–PD-1 and anti–CTLA-4 agents.

Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma

November 29th 2021

Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achieved with infigratinib, and the next steps for this agent.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer

November 29th 2021

Key opinion leaders in gastric cancers comment on ESMO 2021 updates in metastatic HER2+ esophagogastric adenocarcinoma and metastatic HER2+ gastric or gastroesophageal junction cancer.

Frontline Cabozantinib Plus Atezolizumab Shows Favorable Survival in Advanced HCC

November 26th 2021

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival and a numerical improvement in overall survival vs sorafenib as frontline treatment in patients with advanced hepatocellular carcinoma, according to findings from the first planned analysis of the phase 3 COSMIC-312 trial.